Matches in Wikidata for { <http://www.wikidata.org/entity/Q92109434> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- Q92109434 description "artículu científicu espublizáu n'abril de 2020" @default.
- Q92109434 description "scientific article published on 21 April 2020" @default.
- Q92109434 description "wetenschappelijk artikel" @default.
- Q92109434 description "наукова стаття, опублікована 21 квітня 2020" @default.
- Q92109434 name "A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis" @default.
- Q92109434 name "A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis" @default.
- Q92109434 type Item @default.
- Q92109434 label "A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis" @default.
- Q92109434 label "A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis" @default.
- Q92109434 prefLabel "A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis" @default.
- Q92109434 prefLabel "A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis" @default.
- Q92109434 P1433 Q92109434-6DC876AB-1AD7-4610-8496-31B7F9DE1856 @default.
- Q92109434 P1476 Q92109434-2596A5F5-38C3-4B40-9DE1-31EB2827352E @default.
- Q92109434 P2093 Q92109434-1622A2FA-A665-4115-AC8A-CF647E435769 @default.
- Q92109434 P2093 Q92109434-2B128689-4894-4D63-B600-137849AEB6DC @default.
- Q92109434 P2093 Q92109434-66B065A4-D0C0-4FB5-981E-6D415B0E7822 @default.
- Q92109434 P2093 Q92109434-735434CA-FA66-4C0D-905C-2DFF932435EA @default.
- Q92109434 P2093 Q92109434-A81E95BC-3CFC-465F-A157-11EE0987CA23 @default.
- Q92109434 P2093 Q92109434-E8471C2E-4DEB-43E4-AAF5-E71E219B37CB @default.
- Q92109434 P275 Q92109434-6BC36481-9780-4828-B236-8AF694B0EFC1 @default.
- Q92109434 P304 Q92109434-45FE18AC-8B0D-4CF9-80CD-CF90C4F4817F @default.
- Q92109434 P31 Q92109434-2B4503E9-5049-4398-9EE0-E17719CA633B @default.
- Q92109434 P356 Q92109434-5576223D-CC4A-44C9-8304-0BAEA779ACF7 @default.
- Q92109434 P577 Q92109434-67476F72-0A7B-45BC-A582-9DCCFF41EB8F @default.
- Q92109434 P6216 Q92109434-554C73D6-F640-41E7-B83C-F379ED4C3B76 @default.
- Q92109434 P698 Q92109434-5D0F2B26-3065-4937-A0BA-639DFCE7EB61 @default.
- Q92109434 P921 Q92109434-7919425E-F8B1-4D10-9A29-F4406BEFFCC1 @default.
- Q92109434 P356 09546634.2020.1752888 @default.
- Q92109434 P698 32314628 @default.
- Q92109434 P1433 Q6295084 @default.
- Q92109434 P1476 "A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis" @default.
- Q92109434 P2093 "Alan Brnabic" @default.
- Q92109434 P2093 "Diana Rubel" @default.
- Q92109434 P2093 "Elisabeth Riedl" @default.
- Q92109434 P2093 "Lynda Spelman" @default.
- Q92109434 P2093 "Nicole Burkhardt" @default.
- Q92109434 P2093 "Peter Foley" @default.
- Q92109434 P275 Q24082749 @default.
- Q92109434 P304 "1-7" @default.
- Q92109434 P31 Q13442814 @default.
- Q92109434 P356 "10.1080/09546634.2020.1752888" @default.
- Q92109434 P577 "2020-04-21T00:00:00Z" @default.
- Q92109434 P6216 Q50423863 @default.
- Q92109434 P698 "32314628" @default.
- Q92109434 P921 Q10355321 @default.